In this episode, three pharmaceutical industry experts help us explore the key pressure points in the sector.
Joel Lexchin is a Professor Emeritus in the Faculty of Health at York University in Toronto, Canada. He has authored and co-authored over 140 peer-reviewed papers on a wide range of pharmaceutical topics, from research and development to drug promotion and medicine regulation.
Claudia Martínez is the Head of Research at the Access to Medicine Foundation, a non-profit organisation that seeks to address the availability and affordability of medicine to promote equitable access.
Andy Powrie-Smith is the Executive Director of Communications and Partnerships at the European Federation of Pharmaceutical Industries and Associations (EFPIA), a trade body representing pharmaceutical research-based firms across Europe.
Good Corp, Bad Corp is produced by Speak Productions. The views expressed in this episode represent the interviewees’ own opinions and may not be shared by the podcast host or the production company. Speak Productions has no affiliation with the interviewees and has not paid guests to participate. Care was taken to ensure the accuracy of facts within the episode. This podcast is for informational purposes only.
Thanks for listening to Good Corp, Bad Corp. If you enjoyed today’s episode, please remember to subscribe to our podcast, rate the episode and leave a review on your favourite podcast platform. And if you have ideas for future episodes, please get in touch via LinkedIn or at gabriellebridle@speakmedia.co.uk.
~
Speak Productions’ factchecking process highlighted additional statistics or indicated potential inconsistencies between information referenced in the podcast and online sources, which have been noted below.
• 06:02 – External sources, including articles published in Frontiers in Public Health and the European Journal of Translational Myology, reference various figures for the prevalence of ‘orphan diseases’.
• 06:22 – According to the World Health Organisation and the Community Eye Health Journal, neglected tropical diseases affect around 1 billion people. Other sources, including DNDi and Nature Portfolio, suggest that these figures could be higher.
• 06:37 – This statement could only be confirmed at one source, which references 2018.
• 24:38 – While one 2017 WHO report seems to support the existence of pressure on drug companies in this regard, up-to-date sources specifically confirming this trend could not be found.
